NCT05721989 - A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab | Biotech Hunter

Enrollment

267

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

January 8, 2024

Study Completion Date

January 8, 2024

Conditions

Healthy Participants

Interventions

DRUG

Ziltivekimab B

Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.

DRUG

Ziltivekimab D

Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.

DRUG

Ziltivekimab C

Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.

Trial Locations (2)

1077

ICON Budapest Phase I Unit, Budapest

9728 NZ

ICON - location Groningen, Groningen